Increased Safety Concerns Could Reduce Drug Development Pipelines By 20%, IMS Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The pharmaceutical research firm cites increased regulatory scrutiny and post-marketing commitments as catalyst.